The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland

People living with HIV (PLWH) are a heterogeneous group of immunocompromised persons, yet underrepresented in randomized clinical trials leading to vaccination registration. Detectable HIV viral load and having chronic comorbidities may increase the risk of severe COVID-19 outcomes in this group of patients. We aimed to assess the efficacy and safety of vaccinations against COVID-19 in PLWH. Materials and Methods: We performed a retrospective analysis of medical records of HIV-positive individuals routinely followed up between 1 January 2021 and 30 April 2022 that were at the HIV Outpatient Clinic in Warsaw. The analysis included data on the type and date of administration of subsequent doses of COVID-19 vaccination, adverse vaccine reactions, and the history of SARS-CoV-2 infection. Results: In total, 217 patients were included in the analysis, with a median age of 43 years (IQR: 35.5–51.5 years) and median CD4+ count of 591 cells/uL (IQR: 459.5–745.0 cells/uL). Most of the patients were male (191/217, 88.0%) and were vaccinated with the BNT162b2 vaccine (143/217, 65.9%). None of the patients diagnosed with COVID-19 required hospitalization. Vaccine adverse events (VAE) mostly occurred after the 1st dose (in 33/217 (15.2%)), and none of them were severe or required medical care. Conclusions: In our cohort of patients, vaccination against COVID-19 proved to be safe and effective against a severe course of the disease among people living with HIV. However, vaccination, to a lesser degree, protects against mild SARS-CoV-2 infection. Longer observations are required in order to assess the sustainability of protection against severe COVID-19 in this group of patients.

[1]  I. Boutron,et al.  Efficacy and safety of COVID‐19 vaccines , 2022, The Cochrane database of systematic reviews.

[2]  A. Horban,et al.  Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center , 2022, Vaccines.

[3]  A. Horban,et al.  The Clinical Course and Outcomes of Patients Hospitalized Due to COVID-19 during Three Pandemic Waves in Poland: A Single Center Observational Study , 2022, Journal of clinical medicine.

[4]  J. Kowalska,et al.  Complementary dose of COVID-19 vaccination may prevent SARS-CoV-2 breakthrough infection among previously vaccinated HIV positive persons. , 2022, Przeglad Epidemiologiczny.

[5]  William F. Fadel,et al.  Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study , 2022, BMJ.

[6]  M. Gandhi,et al.  COVID-19 Outcomes and Risk Factors Among People Living with HIV , 2022, Current HIV/AIDS Reports.

[7]  G. Llauradó,et al.  Individuals With Higher CD4/CD8 Ratio Exhibit Increased Risk of Acute Respiratory Distress Syndrome and In-Hospital Mortality During Acute SARS-CoV-2 Infection , 2022, Frontiers in Medicine.

[8]  Jessie K. Edwards,et al.  Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States , 2022, JAMA network open.

[9]  B. Lu,et al.  Acceptance of COVID-19 vaccination and influencing factors among people living with HIV in Guangxi, China: a cross-sectional survey , 2022, BMC Infectious Diseases.

[10]  A. Horban,et al.  The Presence of Either Typical or Atypical Radiological Changes Predicts Poor COVID-19 Outcomes in HIV-Positive Patients from a Multinational Observational Study: Data from Euroguidelines in Central and Eastern Europe Network Group , 2022, Viruses.

[11]  A. Horban,et al.  The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center , 2022, Vaccines.

[12]  L. Galea,et al.  Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada , 2021, AIDS and Behavior.

[13]  Á. Soriano,et al.  Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data , 2021, Infectious Diseases and Therapy.

[14]  J. Tomažič,et al.  National strategies for vaccination against COVID‐19 in people living with HIV in Central and Eastern European region , 2021, HIV medicine.

[15]  Miguel Ángel Martínez,et al.  Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study , 2021, The Lancet HIV.

[16]  S. Madhi,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial , 2021, The Lancet HIV.

[17]  P. Klenerman,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial , 2021, The Lancet HIV.

[18]  A. Mastalerz-Migas,et al.  Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland , 2021, Vaccines.

[19]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[20]  J. Biegel,et al.  Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity , 2021, medRxiv.

[21]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[22]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[23]  D. Cattaneo,et al.  Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV , 2020, HIV medicine.

[24]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[25]  V. Calvez,et al.  Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.